Journal Article Review Epublish
PubMed: 40448815 DOI: 10.1007/s12672-025-02233-8
Ki-67 and 21-gene recurrence score assay in decision making for adjuvant chemotherapy in breast cancer patients.
Discov Oncol 16(1):970
Authors: Mohammad Aghebati, Reza Hossieni, Afsaneh Sadat Makeh, Alireza Shirzadi, Mohammad Esmaeil Akbari
Affiliations
- Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Surgery, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
- Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract
Although significant advances have been made in the molecular subtyping of breast cancers, identification of patients who do not benefit from the chemotherapy is a major challenge. Pioneer studies have examined the predictive value of the clinicopathological factors, such as tumor size, disease stage, the expression levels of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) molecules and more importantly tumor cells proliferation index (Ki-67) to help guide patients' treatment and predict their outcome in the adjuvant chemotherapy setting. However, despite their clinical importance, no consensus is reached on their validity for chemotherapy decision. These challenges have ignited researchers to evaluate genomic signatures, which has led to the introduction of several genomic tests that can now help oncologists to include/exclude chemotherapy from the treatment regimen with more confidence. The present review aims to look back over the literature on the clinical significance of Ki-67 as well as the 21-gene recurrence score assay in identification of breast cancer patients who may benefit from the adjuvant chemotherapy.
MeSH
Genes, Breast Neoplasms, Neoplasms, Decision Making, Drug Therapy, Chemotherapy, Adjuvant, Breast, Therapeutics, Chemotherapy